AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

 AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Shots:

  • The interim data from 18 patients out of 20 in P-II trial evaluating the safety, tolerability, and efficacy of MS1819 (700/1200/2240 mg, qd, for 15 days/dosing level) + PERT aged 12 yrs or older in CF patients for EPI
  • The 1EP & 2EP of the trial demonstrated improvement in CFA, improvement in stool weight, stool consistency, bowel movements, rate of steatorrhea & increased body weight, reduced the symptoms of EPI, improved QoL with safety profile. The results from all 20 patients enrolled in the trial are expected in Q2′ 21
  • The company expects to enrol ~24 CF patients with severe EPI and the study completion is expected in Q1’ 21

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE| Image: AzurRx BioPharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post